Euro: ECB rhetoric and Warsh risk guide downside – ING
Chris Turner at ING argues the ECB is unlikely to drop its tightening rhetoric yet, even if a second September hike might be a mistake. He notes the ECB wants to talk tough to manage inflation dynamics, keeping one hike priced by early next year, and warns EUR/USD could revisit the 1.1325 lows on Kevin Warsh’s comments.
ECB stance keeps Euro under pressure
"As our team have been discussing this week, we think it is too early for the ECB to abandon its tightening rhetoric – even though a second hike in September could be a policy mistake."
"The ECB script remains that last month's rate hike was not an insurance move, and it sounds like the ECB wants to talk tough to ride out this inflation hump and ensure that second-round effects do not emerge."
"That suggests market pricing of one ECB rate hike by early next year can stay in money market curves."
"EUR/USD could make a break back to the 1.1325 lows on Warsh today."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

